



Clinical trial results:

A PHASE 3 RANDOMIZED PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT SUBCUTANEOUS INJECTION IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

Summary

EudraCT number	2012-002798-80
Trial protocol	ES DE GR IT CZ PL FR
Global end of trial date	30 June 2020

Results information

Result version number	v1 (current)
This version publication date	16 July 2021
First version publication date	16 July 2021

Trial information

Trial identification

Sponsor protocol code	IM101-332
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 November 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 June 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the efficacy of abatacept to placebo as assessed by the ACR20 response at Day 169

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and incompliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 June 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 44
Country: Number of subjects enrolled	Brazil: 16
Country: Number of subjects enrolled	Canada: 5
Country: Number of subjects enrolled	Chile: 39
Country: Number of subjects enrolled	Colombia: 14
Country: Number of subjects enrolled	Czechia: 14
Country: Number of subjects enrolled	France: 19
Country: Number of subjects enrolled	Germany: 22
Country: Number of subjects enrolled	Greece: 6
Country: Number of subjects enrolled	Israel: 18
Country: Number of subjects enrolled	Italy: 23
Country: Number of subjects enrolled	Mexico: 66
Country: Number of subjects enrolled	Peru: 15
Country: Number of subjects enrolled	Poland: 18
Country: Number of subjects enrolled	South Africa: 39
Country: Number of subjects enrolled	Spain: 31
Country: Number of subjects enrolled	United States: 100
Worldwide total number of subjects	489
EEA total number of subjects	133

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	439
From 65 to 84 years	50
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

424 Were Randomized and Treated

Period 1

Period 1 title	Blinded Treatment
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Abatacept
------------------	-----------

Arm description:

Abatacept 125mg, self-administered subcutaneously, once weekly

Arm type	Experimental
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

125 mg/mL

Arm title	Placebo
------------------	---------

Arm description:

Placebo, self-administered subcutaneously, once weekly.

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

125mg/syringe

Number of subjects in period 1^[1]	Abatacept	Placebo
Started	213	211
Completed	125	98
Not completed	88	113
Subject request to discontinue treatment	2	3

Consent withdrawn by subject	3	5
Adverse event, non-fatal	1	3
Early Escape: Transitioned to OL period	76	89
Entered Open-Label in error	-	1
Subject no longer met criteria	1	-
Lack of efficacy	5	12

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 424 participants were randomized and treated

Period 2

Period 2 title	Open-Label
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Abatacept

Arm description:

Abatacept 125mg, self-administered subcutaneously, once weekly

Arm type	Experimental
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

125mg/mL

Arm title	Placebo
------------------	---------

Arm description:

Placebo, self-administered subcutaneously, once weekly.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

125mg/syringe

Number of subjects in period 2	Abatacept	Placebo
Started	197	185
Completed	123	121
Not completed	74	64
Consent withdrawn by subject	4	1
Adverse event, non-fatal	2	4
Other Reasons	1	1
Subject request discontinue treatment	4	3
Lost to follow-up	1	2
Ongoing OL treatment at time of analysis	46	45
Lack of efficacy	16	8

Period 3

Period 3 title	Long Term Extension
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Abatacept

Arm description:

Abatacept 125mg, self-administered subcutaneously, once weekly

Arm type	Experimental
Investigational medicinal product name	Abatacept
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

125mg/mL

Arm title	Placebo
------------------	---------

Arm description:

Placebo, self-administered subcutaneously, once weekly.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

125mg/syringe

Number of subjects in period 3	Abatacept	Placebo
Started	113	115
Completed	0	8
Not completed	113	107
Subject request to discontinue treatment	2	-
Consent withdrawn by subject	1	-
Adverse event, non-fatal	1	-
Ongoing treatment at time of analysis	106	100
Lack of efficacy	3	7

Baseline characteristics

Reporting groups

Reporting group title	Abatacept
Reporting group description: Abatacept 125mg, self-administered subcutaneously, once weekly	
Reporting group title	Placebo
Reporting group description: Placebo, self-administered subcutaneously, once weekly.	

Reporting group values	Abatacept	Placebo	Total
Number of subjects	213	211	424
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age Continuous Units: years			
arithmetic mean	51.0	49.8	
standard deviation	± 10.67	± 11.26	-
Sex: Female, Male Units:			
Female	121	112	233
Male	92	99	191
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	1	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	195	198	393
More than one race	18	11	29
Unknown or Not Reported	0	1	1

End points

End points reporting groups

Reporting group title	Abatacept
Reporting group description: Abatacept 125mg, self-administered subcutaneously, once weekly	
Reporting group title	Placebo
Reporting group description: Placebo, self-administered subcutaneously, once weekly.	
Reporting group title	Abatacept
Reporting group description: Abatacept 125mg, self-administered subcutaneously, once weekly	
Reporting group title	Placebo
Reporting group description: Placebo, self-administered subcutaneously, once weekly.	
Reporting group title	Abatacept
Reporting group description: Abatacept 125mg, self-administered subcutaneously, once weekly	
Reporting group title	Placebo
Reporting group description: Placebo, self-administered subcutaneously, once weekly.	

Primary: Proportion of ACR 20 Responders at Day 169

End point title	Proportion of ACR 20 Responders at Day 169
End point description: The American College of Rheumatology (ACR) 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.	
End point type	Primary
End point timeframe: Day 169	

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants				
number (confidence interval 95%)	39.4 (32.9 to 46.0)	22.3 (16.7 to 27.9)		

Statistical analyses

Statistical analysis title	SA of Proportion of ACR 20 Responders at day 169
Comparison groups	Abatacept v Placebo
Number of subjects included in analysis	424
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Estimate of Difference
Point estimate	17.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	8.7
upper limit	25.6

Secondary: Proportion of Health Assessment Questionnaire (HAQ) responders at Day 169

End point title	Proportion of Health Assessment Questionnaire (HAQ) responders at Day 169
-----------------	---

End point description:

Participants were considered responders if their HAQ score decreased at least 0.35 from baseline. The number of HAQ responders was divided by the number of treated participants and expressed as a percentage. Scoring conventions are based on the Standard Disability Index of HAQ/HAQ-DI using the 20 response items. For each of the 8 disability categories there is an "aids/devices" companion variable that is used to record the type of assistance, if any, a participant uses for his/her usual activities. If either "aids/devices" and/or "assistance from another person" are checked for a disability category, the score for this category is set to "2" (much difficulty), if the original score was "0" (no difficulty) or "1" (some difficulty). The HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: percentage of participants				
number (confidence interval 95%)	31.0 (24.8 to 37.2)	23.7 (18.0 to 29.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of ACR 20 responders at Day 169 in the TNFi-naïve

subpopulation

End point title	Proportion of ACR 20 responders at Day 169 in the TNFi-naïve subpopulation
-----------------	--

End point description:

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-naïve participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	84	81		
Units: Percentage of participants				
number (confidence interval 95%)	44.0 (33.4 to 54.7)	22.2 (13.2 to 31.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of ACR 20 responders at Day 169 in the TNFi-exposed subpopulation

End point title	Proportion of ACR 20 responders at Day 169 in the TNFi-exposed subpopulation
-----------------	--

End point description:

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts and a 20% in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 20 responders was divided by the number of treated, TNFi-exposed participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	129	130		
Units: Percentage of participants				
number (confidence interval 95%)	36.4 (28.1 to 44.7)	22.3 (15.2 to 29.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of non-progressors in total PsA-modified SHS at Day 169

End point title	Proportion of non-progressors in total PsA-modified SHS at Day 169
-----------------	--

End point description:

The number of radiographic non-progressors in total PsA-Modified Sharp van der Heijde score (SHS) at Day 169 was divided by the number of treated participants and expressed as a percentage. Non-progression was defined as a change from baseline in total PsA modified SHS ≤ 0 . Early escape participants, and participants with missing data at day 169 were imputed as non-progressors.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants				
number (confidence interval 95%)	42.7 (36.1 to 49.4)	32.7 (26.4 to 39.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of participants achieving a PASI 50 at Day 169 in participants with baseline BSA $\geq 3\%$

End point title	Proportion of participants achieving a PASI 50 at Day 169 in participants with baseline BSA $\geq 3\%$
-----------------	--

End point description:

The number of participants who achieved at least 50% improvement from baseline in Psoriasis Area and Severity Index Arthritis (PASI 50) at Day 169 was divided by the number of treated participants with BSA $\geq 3\%$ and expressed as a percentage. Only participants with $\geq 3\%$ body surface area (BSA) of psoriatic skin involvement at randomization were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	146	148		
Units: Percentage of participants				
number (confidence interval 95%)	26.7 (19.5 to 33.9)	19.6 (13.2 to 26.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportions of ACR 50 and ACR 70 responders at Day 169

End point title	Proportions of ACR 50 and ACR 70 responders at Day 169
End point description:	
The ACR 50 and ACR 70 definition of improvement is a 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 50% or 70% improvement in 3 of the 5 remaining core data set measures (participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, acute phase reactant value). The number of ACR 50 and ACR 70 responders was divided by the number of treated participants and expressed as a percentage. Early escape participants, and participants with missing data at day 169 were imputed as non-responders.	
End point type	Secondary
End point timeframe:	
Day 169	

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants				
number (confidence interval 95%)				
ACR 50	19.2 (14.0 to 24.5)	12.3 (7.9 to 16.8)		
ACR 70	10.3 (6.2 to 14.4)	6.6 (3.3 to 10.0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Mean change from baseline in SF-36 physical and mental components at Day 169

End point title	Mean change from baseline in SF-36 physical and mental
-----------------	--

End point description:

Adjusted mean change in scores on the Short Form 36 physical and mental function assessment (SF-36) from baseline were analyzed from the physical component summary (PCS) mental component summary (MCS). The SF-36 is a participant questionnaire assessing 8 domains of health status: physical functioning, pain, vitality, social functioning, psychological functioning, general health perception, and role limitations due to physical and emotional problems. The instrument can be divided into two summary scores, physical and mental component score. The scores range from 0 to 100, with a higher score indicating better quality of life. The two summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: SF-36 points				
arithmetic mean (standard error)				
PCS	5.11 (\pm 0.637)	3.69 (\pm 0.707)		
MCS	2.56 (\pm 0.826)	2.62 (\pm 0.924)		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of participants with at least one positive immunogenicity response up to Day 169 relative to baseline

End point title	Proportion of participants with at least one positive immunogenicity response up to Day 169 relative to baseline
-----------------	--

End point description:

Blood samples were collected at Days 1, 85 and 169 and assayed for the presence of abatacept-specific antibodies. The number of participants with at least one positive immunogenicity response was divided by the number of treated participants and expressed as a percentage.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	203	198		
Units: Percentage of participants				
number (not applicable)	3.9	8.6		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of participants with AEs at Day 169

End point title	Proportion of participants with AEs at Day 169
End point description: Proportion of participants with AEs at Day 169	
End point type	Secondary
End point timeframe: Day 169	

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants				
number (not applicable)	54.5	53.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of participants with SAEs at Day 169

End point title	Proportion of participants with SAEs at Day 169
End point description: Proportion of participants with SAEs at Day 169	
End point type	Secondary
End point timeframe: Day 169	

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants				
number (not applicable)	2.8	4.3		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of participants with AEs leading to discontinuation at Day 169

End point title	Proportion of participants with AEs leading to discontinuation at Day 169
-----------------	---

End point description:

Proportion of participants with AEs leading to discontinuation at Day 169

End point type	Secondary
----------------	-----------

End point timeframe:

Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants				
number (not applicable)	1.4	1.9		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of participant deaths at Day 169

End point title	Proportion of participant deaths at Day 169
-----------------	---

End point description:

Proportion of participant deaths at Day 169

End point type	Secondary
----------------	-----------

End point timeframe:

Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of participants with marked laboratory abnormalities at Day 169

End point title	Proportion of participants with marked laboratory abnormalities at Day 169
End point description:	Proportion of participants with marked laboratory abnormalities at Day 169
End point type	Secondary
End point timeframe:	Day 169

End point values	Abatacept	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	211		
Units: Percentage of participants				
number (not applicable)	3.2	5.4		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All reported AEs including those that occur more than 56 days after the last dose of study medication

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	ABATACEPT DURING DOUBLE-BLIND PERIOD
-----------------------	--------------------------------------

Reporting group description:

Subject self-administered 125 mg/syringe (125 mg/mL) of Abatacept subcutaneously(SC) once weekly for 24 weeks.

Reporting group title	PLACEBO DURING DOUBLE-BLIND PERIOD
-----------------------	------------------------------------

Reporting group description:

Subject self-administered 125 mg/syringe Placebo matching Abatacept SC once weekly for 24 weeks.

Reporting group title	ABATACEPT DURING OPEN-LABEL PERIOD
-----------------------	------------------------------------

Reporting group description:

All subjects transitioned to the Open-label Period and self-administered 125 mg/syringe (125 mg/mL) of Abatacept subcutaneously (SC) once weekly for 28 weeks.

Reporting group title	ABATACEPT DURING OPEN-LABEL EXTENSION PERIOD
-----------------------	--

Reporting group description:

Subjects self-administered 125 mg/syringe (125 mg/mL) of Abatacept subcutaneously (SC) once weekly during the open label extension period.

Reporting group title	ABATACEPT DURING LONG-TERM EXTENSION PERIOD
-----------------------	---

Reporting group description:

At the end of Open-label Period, subjects entered a one-year, Long-term Extension Period during which only safety data was collected. The protocol was then extended for an additional 3 years in 6 countries in compliance with local regulatory requirements. Subjects self-administered 125 mg/syringe (125 mg/mL) of Abatacept subcutaneously (SC) once weekly.

Serious adverse events	ABATACEPT DURING DOUBLE-BLIND PERIOD	PLACEBO DURING DOUBLE-BLIND PERIOD	ABATACEPT DURING OPEN-LABEL PERIOD
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 213 (2.82%)	9 / 211 (4.27%)	29 / 382 (7.59%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
B-cell lymphoma			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			

subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carcinoma in situ of skin			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colorectal adenocarcinoma			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parathyroid tumour benign			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transitional cell carcinoma			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			

subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Peripheral artery thrombosis			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	1 / 213 (0.47%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated hernia			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Polycystic ovaries			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute chest syndrome			

subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	1 / 213 (0.47%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 213 (0.47%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental overdose			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Meniscus injury			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Dermoid cyst			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Demyelination			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			

subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Meniere's disease			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric mucosa erythema			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Inguinal hernia			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary dilatation			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic fibrosis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Erythrodermic psoriasis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psoriasis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Calculus bladder			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	1 / 213 (0.47%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriatic arthropathy			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	2 / 382 (0.52%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondropathy			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metatarsalgia			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Osteoarthritis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 213 (0.00%)	1 / 211 (0.47%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	2 / 213 (0.94%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii infection			
subjects affected / exposed	1 / 213 (0.47%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epstein-Barr virus infection			

subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	0 / 213 (0.00%)	0 / 211 (0.00%)	0 / 382 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	ABATACEPT DURING OPEN-LABEL EXTENSION PERIOD	ABATACEPT DURING LONG-TERM EXTENSION PERIOD	
Total subjects affected by serious adverse events			
subjects affected / exposed	20 / 322 (6.21%)	17 / 106 (16.04%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
B-cell lymphoma			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoma in situ of skin			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenocarcinoma			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroid tumour benign			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Transitional cell carcinoma subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders Peripheral artery thrombosis subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions Chest pain subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated hernia subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders Anaphylactic reaction subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders Polycystic ovaries			

subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute chest syndrome			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Accidental overdose			

subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Dermoid cyst			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Nervous system disorders			
Demyelination			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Meniere's disease			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			

subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric mucosa erythema			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 322 (0.31%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary dilatation			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic fibrosis			

subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Erythrodermic psoriasis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Calculus bladder			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	3 / 322 (0.93%)	3 / 106 (2.83%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondropathy			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Lumbar spinal stenosis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metatarsalgia			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	4 / 322 (1.24%)	2 / 106 (1.89%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	2 / 322 (0.62%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii infection			

subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epstein-Barr virus infection			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Groin abscess			
subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	1 / 322 (0.31%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 106 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth abscess			

subjects affected / exposed	0 / 322 (0.00%)	1 / 106 (0.94%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	ABATACEPT DURING DOUBLE-BLIND PERIOD	PLACEBO DURING DOUBLE-BLIND PERIOD	ABATACEPT DURING OPEN-LABEL PERIOD
Total subjects affected by non-serious adverse events			
subjects affected / exposed	46 / 213 (21.60%)	47 / 211 (22.27%)	106 / 382 (27.75%)
Vascular disorders			
Hypertension			
subjects affected / exposed	5 / 213 (2.35%)	8 / 211 (3.79%)	10 / 382 (2.62%)
occurrences (all)	5	8	11
Nervous system disorders			
Sciatica			
subjects affected / exposed	1 / 213 (0.47%)	0 / 211 (0.00%)	2 / 382 (0.52%)
occurrences (all)	1	0	2
Respiratory, thoracic and mediastinal disorders			
Catarrh			
subjects affected / exposed	1 / 213 (0.47%)	0 / 211 (0.00%)	1 / 382 (0.26%)
occurrences (all)	1	0	1
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	4 / 213 (1.88%)	2 / 211 (0.95%)	10 / 382 (2.62%)
occurrences (all)	4	2	10
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	9 / 213 (4.23%)	11 / 211 (5.21%)	17 / 382 (4.45%)
occurrences (all)	11	12	19
Upper respiratory tract infection			
subjects affected / exposed	6 / 213 (2.82%)	14 / 211 (6.64%)	23 / 382 (6.02%)
occurrences (all)	7	15	28
Bronchitis			
subjects affected / exposed	7 / 213 (3.29%)	5 / 211 (2.37%)	19 / 382 (4.97%)
occurrences (all)	8	5	20

Influenza			
subjects affected / exposed	4 / 213 (1.88%)	3 / 211 (1.42%)	9 / 382 (2.36%)
occurrences (all)	4	3	11
Pharyngitis			
subjects affected / exposed	0 / 213 (0.00%)	2 / 211 (0.95%)	5 / 382 (1.31%)
occurrences (all)	0	2	5
Urinary tract infection			
subjects affected / exposed	10 / 213 (4.69%)	2 / 211 (0.95%)	10 / 382 (2.62%)
occurrences (all)	12	2	11

Non-serious adverse events	ABATACEPT DURING OPEN-LABEL EXTENSION PERIOD	ABATACEPT DURING LONG-TERM EXTENSION PERIOD	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	122 / 322 (37.89%)	90 / 106 (84.91%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	7 / 322 (2.17%)	9 / 106 (8.49%)	
occurrences (all)	8	10	
Nervous system disorders			
Sciatica			
subjects affected / exposed	1 / 322 (0.31%)	6 / 106 (5.66%)	
occurrences (all)	1	7	
Respiratory, thoracic and mediastinal disorders			
Catarrh			
subjects affected / exposed	2 / 322 (0.62%)	12 / 106 (11.32%)	
occurrences (all)	2	17	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	11 / 322 (3.42%)	12 / 106 (11.32%)	
occurrences (all)	11	20	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	26 / 322 (8.07%)	16 / 106 (15.09%)	
occurrences (all)	32	24	
Upper respiratory tract infection			
subjects affected / exposed	19 / 322 (5.90%)	3 / 106 (2.83%)	
occurrences (all)	20	6	

Bronchitis			
subjects affected / exposed	17 / 322 (5.28%)	15 / 106 (14.15%)	
occurrences (all)	19	18	
Influenza			
subjects affected / exposed	17 / 322 (5.28%)	4 / 106 (3.77%)	
occurrences (all)	18	4	
Pharyngitis			
subjects affected / exposed	10 / 322 (3.11%)	6 / 106 (5.66%)	
occurrences (all)	12	6	
Urinary tract infection			
subjects affected / exposed	12 / 322 (3.73%)	8 / 106 (7.55%)	
occurrences (all)	13	9	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 July 2013	<p>Changed "entering" to "continue into" when describing how subjects can continue the one year long term extension (Section 3.1.4).</p> <p>Added azathioprine as a medication which must be discontinued 28 days or five half lives prior to randomization.</p> <p>Deleted study from the breast cancer screening exclusion.</p> <p>Added "prior to randomization (Day 1) to exclusions from Medical History Exclusion Criteria n, q, and v [Section 3.3.2, Subsection 2)].</p> <p>Added an exclusion for treatment with phototherapy within 28 days prior to randomization and hypersensitivity to investigational product excipients.</p> <p>Added that the target lesion must not be in the axilla, genitals, groins, palms, or soles.</p> <p>Changed dose reduction to dose limitation in the definition of intolerance for prior use of DMARDs.</p> <p>Changed information on methods of contraception based on new language currently in discussion (protocol body and Appendix 2).</p> <p>Clarified criteria for missed doses requiring discontinuation of treatment to be consistent throughout the protocol.</p> <p>Added that subjects should avoid taking MTX within 48 hours of study drug administration to simplify determination of relatedness of adverse events to the study drug.</p>
22 July 2013	<p>Added the hyaluronic acid is not permitted in the double-blind and open label periods.</p> <p>Added storage conditions for investigational drug in the Study Treatment section.</p> <p>Changed procedure guide to instructions to describe how subjects will be trained in the use of the safety syringe.</p> <p>Changed caretaker to caregiver in Section 4.3 to be consistent with other language in the protocol.</p> <p>Added immunogenicity to information for which the BMS Bioanalytical Science Department or designee will be unblinded.</p> <p>Added note that the Physician and Subject Global Assessments if Disease Activity refers to arthritis as the disease (Table 5.1-2, Table 5.1-3, and Section 5.4.4.)</p> <p>Added note that subjects should not apply emollients to the skin on the day of their office visits (Table 5.1-2, Table 5.1-3, and Section 5.4.4).</p> <p>Changed description of OL-1 to correctly refer to "Same day as final day in the Double Blind Period.</p> <p>Deleted urine pregnancy test in OL-1 since the testing is already done on the last day in the double blind period.</p> <p>Corrected table note references for Dosing Injectable Study Medication in Table 5.1-3.</p> <p>Added into table notes regarding provisioning of urine pregnancy</p>

29 October 2013	<p>Modified definition of menopause to be 12 months amenorrhea rather than 6 months.</p> <p>Added prior treatment of briakinumab as an exclusion criteria.</p> <p>Indicated the Target Lesion should be assessed in addition to be identified at screening.</p> <p>Added window the Day 1 radiograph to be - 3 days.</p> <p>Corrected PK/PD substudy flow chart to delete information indicating a PK sample is collected at Day 169.</p> <p>Clarified that the clinical assessor for enthesitis, dactylitis, PASI, target lesion, and physician visual analog scales may be a different person from the joint assessor.</p> <p>Added a window for the biopsy sample collection to be - 3 days on Days 1 and 169.</p> <p>Clarified when pregnancy tests are required.</p> <p>Corrected PK table 5.5.1-1 to add sample collection and testing at Early Termination in the double-blind period.</p>
19 August 2014	<p>Changed screening period from 7-42 to 7-56 days.</p> <p>Added permission for rescreening.</p> <p>Modified inclusion criteria for target lesion to be at screening and randomization/Day 1.</p> <p>Changed exclusion criteria for subjects who have been exposed to more than 2 TNFi to specify subjects who have failed more than 2 TNFi due to inefficacy.</p> <p>Changed drug stabilization time for prior use of TNFis.</p> <p>Deleted exclusion of prior use of apremilast, ustekinumab, and briakinumab.</p> <p>Added drug stabilization time for prior use of apremilast, ustekinumab, and briakinumab.</p> <p>Changed TB testing to allow use of a gamma release assay.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported